Trial Profile
A multi-centre, double-blind, randomised, controlled clinical trial of rifaximin to reduce infection in patients admitted to hospital with decompensated cirrhosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Sep 2023
Price :
$35
*
At a glance
- Drugs Rifaximin (Primary)
- Indications Liver cirrhosis
- Focus Therapeutic Use
- Acronyms R-RID
- 26 Mar 2019 Status changed from active, no longer recruiting to completed.
- 26 Mar 2019 Status changed from recruiting to active, no longer recruiting.
- 16 Mar 2017 New trial record